Halozyme Therapeutics
HALO84
$54.52arrow_drop_up1.30%$0.70
High Quality
HALO84
$54.52
arrow_drop_up1.30%Performance History
| Key Stats | |
|---|---|
| Open | $53.23 |
| Prev. Close | $53.75 |
| EPS | 3.43 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 52.48 | 54.64 |
| 52 Week Range | 32.83 | 68.47 |
| Ratios | |
|---|---|
| EPS | 3.43 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Halozyme Therapeutics (HALO)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
- Headquarters
- San Diego
- Employees
- 393
- Exchange
- NASDAQ
Keep an eye on Halozyme Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Halozyme Therapeutics 's (HALO) price per share?
The current price per share for Halozyme Therapeutics (HALO) is $54.52. The stock has seen a price change of $0.7 recently, indicating a 1.3% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Halozyme Therapeutics (HALO)?
For Halozyme Therapeutics (HALO), the 52-week high is $68.47, which is 25.58% from the current price. The 52-week low is $32.83, the current price is 66.07% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Halozyme Therapeutics (HALO) a growth stock?
Halozyme Therapeutics (HALO) has shown an average price growth of -1.65% over the past three years. It has received a score of 76 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Halozyme Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Halozyme Therapeutics (HALO) stock price performance year to date (YTD)?
As of the latest data, Halozyme Therapeutics (HALO) has a year-to-date price change of 14.04%. Over the past month, the stock has experienced a price change of -6.34%. Over the last three months, the change has been -6.8%. Over the past six months, the figure is 11.27%. Looking at a longer horizon, the five-year price change stands at 121.63%.
help
Is Halozyme Therapeutics (HALO) a profitable company?
Halozyme Therapeutics (HALO) has a net income of $444.09M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 84.3% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 58.89% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.02B, with a revenue growth rate of 22.44%, providing insight into the company's sales performance and growth. The gross profit is $855.91M. Operating income is noted at $551.48M. Furthermore, the EBITDA is $632.79M.
help
What is the market capitalization of Halozyme Therapeutics (HALO)?
Halozyme Therapeutics (HALO) has a market capitalization of $6.03B. The average daily trading volume is 54.03, indicating the stock's liquidity and investor engagement.